4893 items matching your search terms.

Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofi brate

Scott, R d’Emden, M Best, J Drury, P Ehnholm, C Kesaniemi, A Pardy, C Tse, D Barter, P Taskinen, M-R Copt, S Keech, A on behalf of the FIELD Investigators,

Strategies for maintaining long-term follow-up in a neonatal trial in Australia and New Zealand

Sebastian, L

Strategies for maintaining long-term follow-up in Australia and New Zealand for the INIS trial

Sebastian, LT Duggal-Beri, P Hague, W Darlow, BA Blanco, JA Tarnow-Mordi, WO on behalf of the International Neonatal Immunotherapy Study (INIS) Collaborative Group,

‘Choosing my treatment’: incorporating informational and decision-making needs into a preference compass

Shakespeare, T Lu, J Tang, T Lim, K Mukherjee, R Back, M Gebski, V

Applying subgroup analysis to individual patient decisions

Simes, RJ; Gebski, VJ; Keech, AC

Optimising the assessment of outcomes in surgical trials: objective versus subjective measures of morbidity in a randomised trial of sentinel node biopsy versus axillary clearance in early breast cancer

Smith, M

Patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the SNAC trials

Smith, MJ; Gill, PG; Wetzig, N; Sourjina, T; Simes, RJ; Stockler, MR
, 2007     DOI:10.1111/j.1445-2197.2007.04114_6.x

Optimal duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis

Soon, Y Askie, L Stockler, M Boyer, M

Dealing with the unexpected in randomised clinical trials

Stockler, M

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial

Stockler, M O'Connell, R Nowak, A Goldstein, D Turner, J Wilcken, N Wyld, D Abdi, E Glasgow, A Beale, P Jefford, M Dhillon, H Heritier, S Carter, C Hickie, IB Simes, RJ the ZEST Trial Group,

A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for advanced breast cancer

Stockler, MR Sourjina, T Grimison, P Gebski, V Byrne, M Harvey, V Francis, P Nowak, AK Coates, AS Forbes J, on behalf of the ANZ Breast Cancer Trials Group,

A prognostic index for predicting lung cancer patients with multiple brain metastases who may not benefit from whole brain radiotherapy due to early death

Sundaresan, R Yeghiaian-Alvandi, R Gebski, V

Should preterm babies be delivered in warmer environments? Proposed RCT using a novel randomised time-cluster design (if further evidence is needed to change practice)

Tarnow-Mordi, W

Fighting the common cold together. Should preterm babies be delivered in warmer environments? RCT with a novel randomised time-cluster design (if more evidence is needed to change practice)

Tarnow-Mordi, W Athayde, N Kent, A Gebski, V

ATTAX: randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5-FU or capecitabine in metastatic oesophago-gastric cancer: fi nal results of an AGITG trial

Tebbutt, NC Sourjina, T Strickland, A Van Hazel, G Ganju, V Gibbs, D Gebski, V Munro, S Cummins, M on behalf of the Australasian GI Trials Group,